Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

223.88
BATS BZX Real-Time Price
As of 1:57pm ET
 -0.11 / -0.05%
Today’s Change
184.50
Today|||52-Week Range
256.80
+6.60%
Year-to-Date
AGN Regular Dividend: AGN began trading ex-dividend on 08/16/17. A $0.70 dividend will be paid to shareholders of record as of 08/18/17.
Valeant CEO Confident Divestitures Can Successfully Pare Debt, Skeptics Remain
Aug 17 / TheStreet.com - Paid Partner Content
Black, Jewish Goldman Executive Sues Firm Over Discriminatory Practices
Aug 16 / TheStreet.com - Paid Partner Content
PayPal, Marriott International, Randgold Resources: 'Mad Money' Lightning Round
Aug 16 / TheStreet.com - Paid Partner Content
Pressing AGN Again
Aug 16 / TheStreet.com - Paid Partner Content
Valeant Pharmaceuticals: Cramer's Top Takeaways
Aug 16 / TheStreet.com - Paid Partner Content
Teva Is Cheap, Not Dead
Aug 16 / TheStreet.com - Paid Partner Content
The Market Is Not About Washington: Cramer's 'Mad Money' Recap (Wed 8/16/17)
Aug 16 / TheStreet.com - Paid Partner Content
Mid Afternoon Musings
Aug 15 / TheStreet.com - Paid Partner Content
Shire Files Marketing Application for Lifitegrast in Europe
Aug 16 / Zacks.com - Paid Partner Content
Are Amgen's New Drugs Doing Well Enough to Drive Sales?
Aug 15 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close223.99
Today’s open223.88
Day’s range222.47 - 225.13
Volume54,900
Average volume (3 months)2,171,981
Market cap$74.9B
Dividend yield1.25%
Data as of 1:57pm ET, 08/21/2017

Growth & Valuation

Earnings growth (last year)+281.42%
Earnings growth (this year)+20.19%
Earnings growth (next 5 years)+15.23%
Revenue growth (last year)-3.32%
P/E ratioNM
Price/Sales5.55
Price/Book1.05

Competitors

 Today’s
change
Today’s
% change
AZNAstraZeneca-0.16-0.55%
ABTAbbott Laboratories+0.05+0.10%
LLYEli Lilly and Co+0.01+0.01%
NVONovo Nordisk+0.31+0.69%
Data as of 1:57pm ET, 08/21/2017

Financials

Next reporting dateNovember 1, 2017
EPS forecast (this quarter)$4.18
Annual revenue (last year)$14.6B
Annual profit (last year)$15.0B
Net profit margin-6.46%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
Chairman, President &
Chief Executive Officer
Brenton L. Saunders
Chief Operating Officer
Robert A. Stewart
Corporate headquarters
Dublin, Dublin

Forecasts